News

PARP Inhibitors: Usurping DNA Repair to Target Cancer

Publish date: June 3, 2011

 

The emerging role for PARP inhibitors in BRCA-mutated cancers is reviewed by Community Oncology Editor-in-Chief Dr. Lee Schwartzberg.

Editor-in-Chief Lee S. Schwartzberg, M.D., is the research medical director at The West Clinic in Memphis, TN.

Download the PARP Inhibitors Powerpoint Slideshow

(3.1MB)

Recommended Reading

Bone Micrometastases Show No Survival Impact in Early Breast Cancer
Breast Cancer ICYMI
NCCN Breast Guidelines Stand by Bevacizumab
Breast Cancer ICYMI
Sequencing Reveals MAP3K1 Mutation in Luminal-Type Breast Cancer
Breast Cancer ICYMI
Radioactive Seeds Guide Surgeons to Nonpalpable Breast Lesions
Breast Cancer ICYMI
Genentech Appeals to FDAs Regulatory Flexibility on Avastin
Breast Cancer ICYMI
CDER: Avastin Breast Cancer Claim Undermines Approval Process
Breast Cancer ICYMI
Low Vitamin D Associated With Poor Prognostic Features in Breast Cancer
Breast Cancer ICYMI
Point/Counterpoint: Does Surgery Improve Survival in Stage IV Breast Cancer?
Breast Cancer ICYMI
Two Studies Find Beta-Blockers Help Combat Breast Cancer Progression
Breast Cancer ICYMI
A Phase II Tolerability Trial of Neoadjuvant Docetaxel with Carboplatin and Capecitabine in Locally Advanced Breast Cancer
Breast Cancer ICYMI